Imophoron Ltd

We’re thrilled to announce the grant of a pivotal patent by the Japan Patent Office for our ADDomer™ platform, marking a major milestone in our mission to advance thermostable nanoparticle vaccines. This exclusive patent strengthens our IP portfolio, extending protection until 2037 and reinforcing our position in global markets.   With patents secured in the US, Europe, and now Japan, Imophoron Ltd is well-positioned to continue developing groundbreaking vaccines for viral infections and other urgent healthcare needs. 🔗 For more details, visit our website: www.imophoron.com

🚀 🚀 We’re thrilled to announce two major developments: 1 - Dr. Steve Chatfield has joined Imophoron Ltd as our new Chair of the Board. With over 40 years of life sciences expertise and a proven track record in vaccine development and emergency preparedness, Steve’s leadership will be pivotal as we advance our mission to develop next-generation vaccines. 2 - We’ve been awarded an Innovate UK grant to develop a thermostable intranasal RSV vaccine using our proprietary ADDomer™ platform. This grant will support the initial stages of formulation development, moving us closer to in vivo trials. Intranasal vaccines offer the potential for superior protection against respiratory diseases, and the intrinsic thermostability of ADDomer makes it ideal for global distribution. These milestones bring us closer to delivering impactful, innovative vaccines that address critical global health challenges. 🌍💉 For full details, check out our press release here: https://lnkd.in/eeCzw2wA #vaccineinnovation #biotech #lifesciences #RSV #vaccinedevelopment #healthcareinnovation #Imophoron

Imophoron Ltd notes the recent publication in Science Magazine of an important scientific paper on the critical role of thermostability in global vaccine distribution. The paper, "Improving vaccine equity by increasing vaccine thermotolerance profiles," includes authors from CEPI (Coalition for Epidemic Preparedness Innovations) and the Tony Blair Institute for Global Change, and addresses the challenges of vaccine temperature sensitivities and proposes solutions to enhance vaccine stability and accessibility worldwide. Richard Bungay, CEO of Imophoron Ltd, remarked, “Imophoron is pleased to be at the forefront of developing nanoparticle vaccines with intrinsic thermostability, utilising its ADDomer™ technology.”  🔗 Link to the Paper: https://lnkd.in/edKKKgNb 🔗 Link to our Press Release: https://lnkd.in/eHis-SjQ

Our CEO, Richard Bungay, was invited to join the Future of Healthcare Investment Forum last week, hosted by the London Stock Exchange. A range of speakers and panellists discussed the continuing challenges of accessing adequate finance to support the world-class R&D being undertaken in the UK. Richard brought his extensive experience of fundraising to a panel titled “Financing Healthcare – UK, US, Private and Public”, and highlighted some of the financing issues facing innovative UK companies developing future healthcare innovations, such as Imophoron Ltd.

We recently had the honour of hosting Lara Lewington and Jonathan Coates of the BBC Click team in our Bristol labs as they explored how technology is playing a role in developing new vaccines utilising Imophoron Ltd's ADDomer platform.   Lara and Jonathan also visited our collaborators at the University of Bristol, where they learned about the use of cryogenic electron microscopy and Cloud computing to reveal the structure of ADDomer-based vaccines.   We are excited to share that the episode has now gone live on BBC iPlayer and can be found here, https://lnkd.in/gHipFD6A, where you can see much of the Imophoron Ltd team, in order of appearance: Charlotte Fletcher, Georgia Balchin, Imre Berger, Richard Bungay, Gemma Alderson, Kapil G., and Frédéric GARZONI.

🔬 Our latest scientific paper publication highlighting the use of the ADDobody scaffold as a new nanobody platform 🔬   We are pleased to announce the publication in Structure of a scientific research paper demonstrating the potential to expand the scope of therapeutic applications for ADDomer, with the engineering of a new synthetic nanobody called ADDobody.   📄 Title: Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders 🔗 Link to the Paper: https://lnkd.in/e4nDzrGA   This programme, carried out in collaboration with the University of Bristol, combined synthetic and structural biology methods with selection using ribosome display to produce and validate high-avidity super-binders for detection, binding, and neutralisation of diverse pathogenic or toxic targets, such as snake venom.   Let's continue to push for novel new treatments to address major unmet medical needs. #Innovation #HealthcareAdvancements #nanoparticles #biotechinnovation

🚀🌐 🔬 We are delighted to announce a major milestone at Imophoron Ltd: the European Patent Office has granted a pivotal patent, covering fundamental claims related to the use of our ADDomer technology for vaccine development. The patent, titled " Adenoviral coat protein-derived delivery vehicles," is exclusively licensed to us from Centre national de la recherche scientifique and EMBL European Molecular Biology Laboratory and provides us with exclusivity until 2036.   🔗 For more details, visit our website: www.imophoron.com   Thank you for your ongoing support as we continue to innovate and make a positive impact in healthcare! 💙🌍 #Innovation #HealthcareAdvancements #VaccineDevelopment #PatentNews

🔬 Our latest scientific paper publication highlights the ability of ADDomer to combat viral infections 🔬   We are delighted to announce the publication in Antibody Therapeutics of a scientific research paper demonstrating the potential for the broad application of ADDomer in generating intrinsically thermostable vaccines and reagents to combat viral infections.   📄 Title: In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2 🔗 Link to the Paper: https://lnkd.in/dchDD9hJ   This paper explores the cutting-edge technology behind the development of an ADDomer vaccine targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This programme, carried out in collaboration with the University of Bristol, involved an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunisation to design, produce and validate nature-inspired nanoparticle-based vaccines and reagents. The paper highlights the use of Imophoron Ltd’s patented multivalent nanoparticle superbinder technology against SARS-CoV-2, including immune-evasive variants of concern.   We invite you to read the full paper https://lnkd.in/dchDD9hJ, and we’re eager to hear your thoughts and insights. Let's continue pushing the boundaries of knowledge and innovation together!

We are thrilled to share that Imophoron Ltd’s CEO, Richard Bungay, has been featured in PIR International's BioLeader interview series. 🚀 In this insightful conversation, Richard shares his approach to working in the life sciences industry and the experiences that have shaped his career and outlook.💡 #Leadership #Innovation #IndustryInsights #CEOInterview #Imophoron #vaccines #biotech #lifescience